NI201100150A - Sistemas basados en conjugados para entrega farmacológica controlada. - Google Patents
Sistemas basados en conjugados para entrega farmacológica controlada.Info
- Publication number
- NI201100150A NI201100150A NI201100150A NI201100150A NI201100150A NI 201100150 A NI201100150 A NI 201100150A NI 201100150 A NI201100150 A NI 201100150A NI 201100150 A NI201100150 A NI 201100150A NI 201100150 A NI201100150 A NI 201100150A
- Authority
- NI
- Nicaragua
- Prior art keywords
- conjugate
- based systems
- pharmacological delivery
- controlled
- controlled pharmacological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Conjugados que comprenden un fármaco y un ligando el cual incluye un primer sacárido; en donde el conjugado se caracteriza en que, al administrarse el conjugado en un mamífero, por lo menos una propiedad farmacocinética o farmacodinámica del conjugado es sensible a la concentración sérica de un segundo sacárido. Se proporcionan conjugados y formulaciones de liberación sostenida de ejemplo además de métodos de uso y preparación.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14787809P | 2009-01-28 | 2009-01-28 | |
US15964309P | 2009-03-12 | 2009-03-12 | |
US16210709P | 2009-03-20 | 2009-03-20 | |
US16308409P | 2009-03-25 | 2009-03-25 | |
US21989709P | 2009-06-24 | 2009-06-24 | |
US22357209P | 2009-07-07 | 2009-07-07 | |
US25285709P | 2009-10-19 | 2009-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201100150A true NI201100150A (es) | 2011-11-09 |
Family
ID=42395986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201100150A NI201100150A (es) | 2009-01-28 | 2011-07-27 | Sistemas basados en conjugados para entrega farmacológica controlada. |
Country Status (24)
Country | Link |
---|---|
US (5) | US9050370B2 (es) |
EP (1) | EP2391218B1 (es) |
JP (3) | JP5508438B2 (es) |
KR (2) | KR101635689B1 (es) |
CN (2) | CN102365025A (es) |
AU (2) | AU2015202872B2 (es) |
BR (1) | BRPI1007457A2 (es) |
CA (2) | CA2932926C (es) |
CO (1) | CO6400173A2 (es) |
CR (1) | CR20110408A (es) |
DO (1) | DOP2011000244A (es) |
EA (1) | EA027757B1 (es) |
EC (1) | ECSP11011240A (es) |
ES (1) | ES2791683T3 (es) |
GT (1) | GT201100208A (es) |
IL (1) | IL214099A0 (es) |
MA (1) | MA33064B1 (es) |
MX (1) | MX2011007929A (es) |
NI (1) | NI201100150A (es) |
NZ (1) | NZ594248A (es) |
PE (1) | PE20120583A1 (es) |
SG (3) | SG173112A1 (es) |
TN (1) | TN2011000354A1 (es) |
WO (1) | WO2010088294A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010088268A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
AU2010208305A1 (en) | 2009-01-28 | 2011-09-08 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
US9050370B2 (en) | 2009-01-28 | 2015-06-09 | Smartcells, Inc. | Conjugate based systems for controlled drug delivery |
CA2754950A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
US9095623B2 (en) | 2009-03-20 | 2015-08-04 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
CA2805902A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
CA2805743A1 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
JP2013542915A (ja) * | 2010-07-28 | 2013-11-28 | スマートセルズ・インコーポレイテツド | 薬物−リガンドコンジュゲート、その合成およびその中間体 |
CA2806399A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
US20130302825A1 (en) * | 2010-10-14 | 2013-11-14 | Merck | Uses of macrophage mannose receptor to screen compounds and uses of these compounds |
AR087433A1 (es) * | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
TWI439288B (zh) * | 2012-10-05 | 2014-06-01 | Univ China Medical | 藥用載體及其製備方法與用途 |
EP2925722A4 (en) * | 2012-11-28 | 2016-07-06 | Victoria Link Ltd | COMPOUNDS AT DENDRITIC |
JP6735561B2 (ja) | 2012-12-03 | 2020-08-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | O−グリコシル化カルボキシ末端部分(ctp)ペプチド系のインスリンおよびインスリン類似体 |
JP2016506927A (ja) * | 2013-01-22 | 2016-03-07 | ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University | N末端短縮型インスリン類似体 |
CA2924743A1 (en) * | 2013-10-04 | 2015-04-09 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
WO2016164288A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
BR112018074716A2 (pt) * | 2016-06-02 | 2019-03-12 | Sanofi | conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose |
DK3570874T3 (da) * | 2017-01-17 | 2023-04-11 | Univ Wayne State | Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder |
EP3600381A4 (en) * | 2017-03-23 | 2021-06-16 | Merck Sharp & Dohme Corp. | GLUCOSE-ACTIVE INSULIN WITH A THREE-VALUE SUGAR CLUSTER FOR THE TREATMENT OF DIABETES |
WO2018174725A1 (en) | 2017-03-23 | 2018-09-27 | Victoria Link Limited | Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses |
WO2019106122A1 (en) | 2017-12-01 | 2019-06-06 | Sanofi | Novel conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
EP3727424A4 (en) * | 2017-12-18 | 2021-10-27 | Merck Sharp & Dohme Corp. | CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE |
CN108610494B (zh) * | 2018-03-20 | 2020-11-06 | 南京理工大学 | 聚醚砜/功能性含糖聚合物杂化膜的制备方法 |
CN110146605A (zh) * | 2019-04-19 | 2019-08-20 | 南通联亚药业有限公司 | 一种测定格列吡嗪原料药及其缓释片中特定基因毒性杂质的分析方法 |
CN112480184A (zh) * | 2020-12-09 | 2021-03-12 | 上海应用技术大学 | 一种利用梯度点击化学合成含多种糖的树枝化糖胺的方法 |
JP2024518909A (ja) | 2021-05-05 | 2024-05-08 | ノボ・ノルデイスク・エー/エス | グルコース感受性インスリンのための残存インスリン |
WO2024096408A1 (ko) * | 2022-11-01 | 2024-05-10 | 주식회사 삼양홀딩스 | 아마이드 및 에스터 작용기를 갖는 지질 및 이의 제조방법 |
KR20240072916A (ko) * | 2022-11-16 | 2024-05-24 | 주식회사 삼양홀딩스 | 약물 전달용 나노입자 조성물 |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US39055A (en) | 1863-06-30 | Improvement in churns | ||
US3591574A (en) | 1968-05-29 | 1971-07-06 | American Home Prod | Tri-n-phenylglycyl derivatives of insulin |
DE1793517C3 (de) | 1968-09-28 | 1974-12-05 | Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt | N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung |
US3697502A (en) | 1969-11-03 | 1972-10-10 | Christensen Henry M | Method of making iron dextran-preparations |
US3847890A (en) | 1971-11-01 | 1974-11-12 | A Green | Acidic monosaccharide-substituted proteins |
US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
US4377567A (en) | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
DE2964024D1 (en) | 1978-10-02 | 1982-12-16 | Procter & Gamble | Liposomes for drug delivery and composition containing a liposome drug system |
US4348387A (en) * | 1979-07-31 | 1982-09-07 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
US4421685A (en) | 1980-03-27 | 1983-12-20 | Eli Lilly And Company | Process for producing an insulin |
JPS608000B2 (ja) | 1980-04-11 | 1985-02-28 | 呉羽化学工業株式会社 | アミノフエニル誘導体及び該誘導体を含有する生理活性剤 |
US4435173A (en) | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
US4498843A (en) | 1982-08-02 | 1985-02-12 | Schneider Philip H | Insulin infusion pump |
US4444683A (en) | 1982-11-17 | 1984-04-24 | University Of Utah | Glycosylated insulin derivatives |
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
EP0119650A3 (en) | 1983-03-21 | 1987-09-30 | THE PROCTER & GAMBLE COMPANY | Galactosyl-insulin conjugates useful in treating diabetics |
US4863896A (en) | 1984-05-03 | 1989-09-05 | Technology Unlimited, Inc. | Diabetic control by combined insulin forms |
DK160633C (da) | 1985-05-15 | 1991-09-02 | Henning Munk Ejlersen | Slangepumpe, isaer til avendelse som insulinpumpe |
US5239062A (en) | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
US5395924A (en) | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
US5062841A (en) | 1988-08-12 | 1991-11-05 | The Regents Of The University Of California | Implantable, self-regulating mechanochemical insulin pump |
DK111489D0 (da) | 1989-03-08 | 1989-03-08 | Novo Nordisk As | Peptider |
AU628674B2 (en) | 1989-10-19 | 1992-09-17 | Nippon Oil And Fats Company, Limited | Polymer complexes of a sugar response type |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
RU2003351C1 (ru) * | 1991-06-26 | 1993-11-30 | Липов Борис Петрович; Сафронов Игорь Николаевич | Инъектор |
GB9200638D0 (en) | 1992-01-10 | 1992-03-11 | Leicester Polytechnic | Drug system |
CA2107683C (en) | 1992-02-13 | 2004-07-20 | Dale G. Swan | Immobilization of chemical species in crosslinked matrices |
GB9316895D0 (en) | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
GB9313484D0 (en) | 1993-06-30 | 1993-08-11 | Univ Montfort | Drug system ii |
US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
WO1995007931A1 (en) * | 1993-09-17 | 1995-03-23 | Novo Nordisk A/S | Acylated insulin |
US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
AR002976A1 (es) | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
US5902603A (en) | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
JP2000501414A (ja) | 1995-11-22 | 2000-02-08 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 生体分子の細胞取り込みを高めるリガンド |
US5723589A (en) | 1995-12-21 | 1998-03-03 | Icn Pharmaceuticals | Carbohydrate conjugated bio-active compounds |
US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
EP0954589A1 (en) | 1997-01-24 | 1999-11-10 | Novo Nordisk A/S | Synthetic leader peptide sequences |
ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
JP2001521006A (ja) | 1997-10-24 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 不溶性インシュリン組成物 |
ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
AU1870099A (en) | 1998-01-09 | 1999-07-26 | Novo Nordisk A/S | Stabilised insulin compositions |
ES2245824T3 (es) | 1998-04-15 | 2006-01-16 | Novo Nordisk A/S | Nuevo proceso de separacion de proteinas utilizando un eluyente que contiene ca++. |
US6300319B1 (en) * | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
US6844166B1 (en) | 1998-09-11 | 2005-01-18 | Sensor Technologies Inc. | Recombinant reduced valency carbohydrate binding ligands |
US6323311B1 (en) | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
US6777207B2 (en) | 1999-12-29 | 2004-08-17 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast |
US6521738B2 (en) | 1999-12-29 | 2003-02-18 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogs |
JP2003535106A (ja) * | 2000-06-02 | 2003-11-25 | ノボ ノルディスク アクティーゼルスカブ | グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出 |
US7316999B2 (en) | 2000-06-02 | 2008-01-08 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
US6650951B1 (en) | 2000-06-19 | 2003-11-18 | International Business Machines Corporation | Method and insulin pump for providing a forgotten bolus warning |
AU2001280552A1 (en) | 2000-07-13 | 2002-01-30 | The Ohio State University Research Foundation | Multimeric biopolymers as structural elements, sensors and actuators in microsystems |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
AU2002258490A1 (en) | 2001-03-12 | 2003-06-17 | Clemson University | Polysaccharide-based polmerizable hydrogels |
US7105314B2 (en) | 2001-04-02 | 2006-09-12 | Novo Nordisk A/S | Method for making human insulin precursors |
EP2279755B1 (en) * | 2001-10-10 | 2014-02-26 | ratiopharm GmbH | Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF) |
US7311892B2 (en) | 2001-10-26 | 2007-12-25 | The Uab Research Foundation | Multidrug multiligand conjugates for targeted drug delivery |
US6736796B2 (en) | 2001-11-26 | 2004-05-18 | Nili-Med Ltd. | Fluid drug delivery device |
US7473680B2 (en) * | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US7317000B2 (en) | 2001-12-02 | 2008-01-08 | Novo Nordisk A/S | Glucose-dependent insulins |
AU2002349295A1 (en) * | 2001-12-02 | 2003-06-17 | Novo Nordisk A/S | Glucose dependant release of insulin from glucose sensing insulin derivatives |
JP3869828B2 (ja) | 2001-12-07 | 2007-01-17 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信端末、アプリケーションプログラムの実行状態制御方法、アプリケーションプログラム、及びアプリケーションプログラムを記録した記録媒体 |
US6852104B2 (en) | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
US6744350B2 (en) | 2002-02-28 | 2004-06-01 | Smiths Medical Md, Inc. | Insulin pump having missed meal bolus alarm |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
ES2360182T3 (es) | 2002-05-07 | 2011-06-01 | Novo Nordisk A/S | Formulaciones solubles que comprenden insulina monomérica e insulina acilada. |
AU2003263793A1 (en) | 2002-07-19 | 2004-02-09 | Lg Life Sciences | Dendrimers as molecular translocators |
US7993108B2 (en) | 2002-10-09 | 2011-08-09 | Abbott Diabetes Care Inc. | Variable volume, shape memory actuated insulin dispensing pump |
AU2002368314A1 (en) * | 2002-10-29 | 2004-05-25 | Ranbaxy Laboratories Limited | Iminosugar derivatives as glucosidase inhibitors |
AU2003301064A1 (en) * | 2002-12-17 | 2004-07-14 | Massachusetts Institute Of Technology | Stimuli-responsive systems for controlled drug delivery |
US7781197B2 (en) | 2002-12-20 | 2010-08-24 | Greenovation Biotech Gmbh | Transformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins |
JPWO2004101619A1 (ja) * | 2003-05-15 | 2006-10-26 | 塩野義製薬株式会社 | 機能的糖ペプチドの合理的設計および合成 |
JP2007532096A (ja) | 2003-11-14 | 2007-11-15 | ノボ ノルディスク アクティーゼルスカブ | アシル化されたインスリンの製造方法 |
WO2006088473A2 (en) | 2004-04-23 | 2006-08-24 | Panduranga Rao Koritala | Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents |
WO2006008238A1 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Method for selective acylation |
CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
US20070207498A1 (en) | 2005-02-24 | 2007-09-06 | Lifescan, Inc. | Design and construction of dimeric concanavalin a mutants |
US20060247154A1 (en) | 2005-02-24 | 2006-11-02 | Lifescan, Inc. | Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same |
WO2006102762A1 (en) | 2005-04-01 | 2006-10-05 | Mcmaster University | Glucose responsive microgels |
BRPI0616630B8 (pt) | 2005-09-30 | 2021-05-25 | Miikana Therapeutics Inc | compostos de pirazol substituídos |
EP1991272A2 (en) | 2005-10-10 | 2008-11-19 | N.V. Organon | Antithrombotic compound |
US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
US7687608B2 (en) | 2005-10-19 | 2010-03-30 | Smartcells, Inc. | Methods for reducing the mitogenicity of lectin compositions |
DE602007009496D1 (de) | 2006-02-27 | 2010-11-11 | Novo Nordisk As | Insulinderivate |
WO2008036147A2 (en) | 2006-07-24 | 2008-03-27 | Duke University | Drug delivery with stimulus responsive biopolymers |
US8299015B2 (en) | 2006-07-25 | 2012-10-30 | Lipoxen Technologies Limited | Derivatisation of granulocyte colony-stimulating factor |
FR2904315B1 (fr) | 2006-07-26 | 2012-12-14 | Centre Nat Rech Scient | Composes pyridaziniques et pyrroliques, procedes d'obtention et applications |
US7515060B2 (en) | 2006-10-17 | 2009-04-07 | Smiths Medical Md, Inc. | Insulin pump for the visually impaired |
US20080172028A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having selectable insulin absorption models |
CN101273961A (zh) | 2007-03-30 | 2008-10-01 | 中国人民解放军总医院 | 葡萄糖敏感水凝胶 |
US20090053167A1 (en) | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
US20090005726A1 (en) | 2007-06-27 | 2009-01-01 | Steven Paul Jones | Insulin Pump Having Expected Bolus Interval and an Early Bolus Interval |
WO2009033588A2 (en) | 2007-09-11 | 2009-03-19 | F. Hoffmann-La-Roche Ag | Self-controlled insulin delivery system |
WO2009059450A1 (en) | 2007-11-05 | 2009-05-14 | Shanghai Jiaotong University | Peptide ligand directed drug delivery |
GB2446247B (en) | 2007-11-27 | 2008-12-17 | Robert Joseph Wagener | Homeostatic insulin pump |
US20090177154A1 (en) | 2008-01-08 | 2009-07-09 | Michael Blomquist | Insulin pump with convenience features |
CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
RU2381238C2 (ru) | 2008-01-31 | 2010-02-10 | Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (статус государственного учреждения) | Способ получения глюкозочувствительных полимерных гидрогелей |
BRPI0822775A2 (pt) | 2008-02-19 | 2015-06-30 | Biocon Ltd | Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa. |
DK2141620T3 (en) | 2008-07-01 | 2019-02-18 | Hoffmann La Roche | Insulin pump and method for controlling one of the insulin pump's user interface |
WO2010088268A1 (en) * | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
US9050370B2 (en) * | 2009-01-28 | 2015-06-09 | Smartcells, Inc. | Conjugate based systems for controlled drug delivery |
AU2010208305A1 (en) * | 2009-01-28 | 2011-09-08 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
JP2012516156A (ja) * | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | ポリヌクレオチドアプタマー系架橋物質体およびその使用 |
CA2750269A1 (en) * | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Crystalline insulin-conjugates |
AU2010208374A1 (en) * | 2009-01-28 | 2011-08-04 | Smartcells, Inc. | Binding-site modified lectins and uses thereof |
US9095623B2 (en) * | 2009-03-20 | 2015-08-04 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
CA2754950A1 (en) * | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
WO2010107520A1 (en) * | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
US20120184487A1 (en) | 2009-06-30 | 2012-07-19 | Novo Nordisk A/S | Insulin derivatives |
CA2806399A1 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
CA2805902A1 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
CA2805743A1 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
CA2924743A1 (en) * | 2013-10-04 | 2015-04-09 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
WO2016164288A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
US9899205B2 (en) * | 2016-05-25 | 2018-02-20 | Kla-Tencor Corporation | System and method for inhibiting VUV radiative emission of a laser-sustained plasma source |
-
2010
- 2010-01-27 US US13/145,532 patent/US9050370B2/en active Active
- 2010-01-27 CA CA2932926A patent/CA2932926C/en not_active Expired - Fee Related
- 2010-01-27 MX MX2011007929A patent/MX2011007929A/es active IP Right Grant
- 2010-01-27 KR KR1020147001684A patent/KR101635689B1/ko active IP Right Grant
- 2010-01-27 KR KR1020117017641A patent/KR20110104081A/ko not_active Application Discontinuation
- 2010-01-27 WO PCT/US2010/022268 patent/WO2010088294A1/en active Application Filing
- 2010-01-27 ES ES10736354T patent/ES2791683T3/es active Active
- 2010-01-27 NZ NZ594248A patent/NZ594248A/en not_active IP Right Cessation
- 2010-01-27 CN CN201080015055XA patent/CN102365025A/zh active Pending
- 2010-01-27 EA EA201170986A patent/EA027757B1/ru not_active IP Right Cessation
- 2010-01-27 SG SG2011053311A patent/SG173112A1/en unknown
- 2010-01-27 JP JP2011548259A patent/JP5508438B2/ja not_active Expired - Fee Related
- 2010-01-27 EP EP10736354.1A patent/EP2391218B1/en active Active
- 2010-01-27 SG SG2014006597A patent/SG2014006597A/en unknown
- 2010-01-27 CA CA2750262A patent/CA2750262C/en not_active Expired - Fee Related
- 2010-01-27 CN CN201610103747.9A patent/CN105753965A/zh active Pending
- 2010-01-27 SG SG2013065412A patent/SG193837A1/en unknown
- 2010-01-27 MA MA34121A patent/MA33064B1/fr unknown
- 2010-01-27 PE PE2011001411A patent/PE20120583A1/es not_active Application Discontinuation
- 2010-01-27 BR BRPI1007457-0A patent/BRPI1007457A2/pt not_active IP Right Cessation
-
2011
- 2011-07-14 IL IL214099A patent/IL214099A0/en unknown
- 2011-07-15 TN TN2011000354A patent/TN2011000354A1/fr unknown
- 2011-07-27 NI NI201100150A patent/NI201100150A/es unknown
- 2011-07-27 GT GT201100208A patent/GT201100208A/es unknown
- 2011-07-28 DO DO2011000244A patent/DOP2011000244A/es unknown
- 2011-07-28 EC EC2011011240A patent/ECSP11011240A/es unknown
- 2011-07-28 CR CR20110408A patent/CR20110408A/es unknown
- 2011-07-28 CO CO11095147A patent/CO6400173A2/es not_active Application Discontinuation
-
2014
- 2014-03-20 JP JP2014057357A patent/JP5834103B2/ja not_active Expired - Fee Related
- 2014-05-30 US US14/291,021 patent/US9265838B2/en active Active
-
2015
- 2015-05-27 AU AU2015202872A patent/AU2015202872B2/en not_active Ceased
- 2015-05-27 AU AU2015202871A patent/AU2015202871B2/en not_active Ceased
- 2015-06-04 US US14/731,016 patent/US9579391B2/en active Active
- 2015-11-02 JP JP2015215913A patent/JP6040301B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-10 US US15/040,004 patent/US20160193351A1/en not_active Abandoned
-
2017
- 2017-08-18 US US15/680,262 patent/US10398781B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201100150A (es) | Sistemas basados en conjugados para entrega farmacológica controlada. | |
CL2011002968A1 (es) | Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion. | |
CL2008002111A1 (es) | Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras. | |
BRPI0910746B8 (pt) | agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica | |
BRPI0813680A2 (pt) | AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO. | |
CL2011003347A1 (es) | Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides. | |
CR9339A (es) | Formas farmaceuticas con propiedades farmacocineticas mejoradas | |
UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
AR061785A1 (es) | Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas | |
GT201300235A (es) | Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas | |
CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. | |
BR112015011946A2 (pt) | dispositivo de conexão | |
NI201000189A (es) | Formulación de medicamento sólido con liberación retardadas. | |
DK1719503T3 (da) | Anvendelse af stivelse med fraspaltede sidekæder i ekstrudering/sfæronisering af farmaceutiske pellets | |
DOP2007000043A (es) | Derivados de cromanol sustituidos y su uso | |
EA201171497A1 (ru) | Снижение флуктуаций опиоидов в крови | |
AR083361A1 (es) | Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon | |
PE20081881A1 (es) | Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos | |
AR092840A1 (es) | Elaboracion de degarelix | |
ES2415029A8 (es) | Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24. | |
SV2008003018A (es) | Formulaciones medicamentosas que contienen fluoroquinolonas | |
ECSP10010661A (es) | Dronedarona para la prevención de la cardioversión | |
CL2008001563A1 (es) | Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras. | |
BRPI0720309A2 (pt) | Análogos de epotilona modificados nas posições c12 - c13 como fármacos anticâncer | |
CO6480929A2 (es) | Procedimiento de uso del factor liberador de corticotropina para el tratamiento del cancer |